Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update

Posted by George Bondi on Aug 26th, 2026

Biorestorative Therapies, Inc. (NASDAQ:BRTX – Get Free Report) was the target of a large drop in short interest in the month of August. As of August 14th, there was short interest totaling 99,687 shares, a drop of 78.5% from the July 30th total of 463,966 shares. Based on an average daily volume of 298,477 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.5% of the shares of the stock are sold short.

Biorestorative Therapies Stock Performance

Shares of NASDAQ:BRTX opened at $0.22 on Wednesday. Biorestorative Therapies has a 52-week low of $0.16 and a 52-week high of $1.89. The firm has a fifty day moving average of $0.30 and a 200 day moving average of $0.30. The firm has a market capitalization of $5.67 million, a PE ratio of -0.21 and a beta of 0.79.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Citadel Advisors LLC bought a new position in shares of Biorestorative Therapies during the third quarter valued at about $152,000. DRW Securities LLC bought a new position in shares of Biorestorative Therapies during the fourth quarter valued at about $55,000. Finally, Virtu Financial LLC lifted its holdings in Biorestorative Therapies by 102.4% in the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after buying an additional 12,319 shares during the period. 69.38% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Monday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Get Our Latest Research Report on Biorestorative Therapies

Biorestorative Therapies Company Profile

(Get Free Report)

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.